December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Unique Polypropylene Packaging System for TRAVATAN® Minimizes Loss to the Container
Author Affiliations & Notes
  • MR Hellberg
    Medicinal Chemistry Alcon Laboratories Fort Worth TX
  • S Airy
    Fort Worth TX
  • JS Chiou
    Fort Worth TX
  • J Clifford
    Fort Worth TX
  • O Gan
    Fort Worth TX
  • R Jani
    Fort Worth TX
  • B Kabra
    Fort Worth TX
  • B McCune
    Fort Worth TX
  • H Nguyen
    Fort Worth TX
  • A Weiner
    Fort Worth TX
  • Footnotes
    Commercial Relationships    M.R. Hellberg, Alcon Laboratories E, P; S. Airy, None; J.S. Chiou , None; J. Clifford , None; O. Gan , None; R. Jani , None; B. Kabra , None; B. McCune , None; H. Nguyen , None; A. Weiner , None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2318. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      MR Hellberg, S Airy, JS Chiou, J Clifford, O Gan, R Jani, B Kabra, B McCune, H Nguyen, A Weiner; Unique Polypropylene Packaging System for TRAVATAN® Minimizes Loss to the Container . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2318.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose:To evaluate stability and compatibility of the ophthalmic prostaglandin analogue, TRAVATAN®,with ethylene oxide (EtO) and gamma sterilized low density polypropylene (LDPE) and polypropylene (PP) packaging materials, and determine the most appropriate packaging container. Methods:A soaking study was carried out using thin slices of EtO and gamma sterilized plastic bottles made from LDPE and PP packaging materials and transferring them into clear glass ampules filled with travoprost solution. The amount of packaging material used in this study provided sufficient surface area to mimic an exposure of solution in a typical 5-mL bottle. The glass ampules were heat-sealed and stressed to 55C for eight weeks in order to speed up the aging process. Analyses of stability samples were conducted using a validated high-pressure liquid chromatography (HPLC) method with isocratic and gradient elution. Results:Travoprost solution stored with gamma sterilized LDPE material showed about 20% decrease in active concentration, and an 8% decrease with EtO sterilized LDPE plastic materials. No significant change in travoprost concentration was observed when stored with EtO sterilized PP material. The unique oval package system designed for TRAVATAN® (U.S. Patent # 6,235,781) is made from a new class of plastic resin called syndiotactic polypropylene (sPP). It showed better flexibility, clarity and exhibited no significant loss of travoprost to the container. Conclusion:TRAVATAN® demonstrates optimum compatibility with sPP bottles. For masked efficacy studies, TRAVATAN® should not be transferred into either gamma or EtO sterilized LDPE plastic bottles. CR: E, P

Keywords: 392 eicosanoids 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.